Tirzepatide and Diet Explored for Crohn's Disease Management

Inflammatory Bowel Disease (IBD), particularly Crohn's disease, is a chronic inflammatory condition of the gastrointestinal tract, often managed with biologics like infliximab or adalimumab. Many patients with Crohn's disease also experience obesity or are overweight, which can complicate disease management and overall health. Current treatments primarily focus on inflammation, but the role of metabolic health and weight loss as an adjunctive therapy for Crohn's disease in patients already on biologics is not well understood. This pilot study aims to investigate if a dual GIP/GLP-1 receptor agonist (Tirzepatide) combined with a Mediterranean diet can improve clinical response in overweight or obese Crohn's patients.

As a recruiting pilot study (NCT ID: NCT06774079), there are no findings yet. However, the study aims to determine the effect of Tirzepatide and a Mediterranean diet on Crohn's disease clinical response. The primary outcome will likely assess changes in disease activity scores, such as the Crohn's Disease Activity Index (CDAI), and potentially endoscopic remission rates. Secondary outcomes are expected to include significant weight loss, improvements in metabolic markers, and patient-reported quality of life. The trial design suggests an investigation into whether this combined approach can lead to a measurable improvement in disease control beyond current biologic therapy alone. This randomized clinical trial is scheduled to run from 2025 to 2027. The study's primary objective is to evaluate if Tirzepatide and a Mediterranean diet can induce a superior clinical response in Crohn's disease patients compared to standard care, specifically looking for reductions in disease activity.